<DOC>
	<DOCNO>NCT02093390</DOCNO>
	<brief_summary>This nonrandomized , open-label , fixed-sequence , 2-arm study design assess effect multiple dose fluconazole atorvastatin single-dose pharmacokinetics TAK-385 healthy adult subject .</brief_summary>
	<brief_title>A Phase 1 Study Evaluate Effects Fluconazole Atorvastatin Pharmacokinetics TAK-385 Healthy Subjects</brief_title>
	<detailed_description>The drug test study call TAK-385 . TAK-385 test assess way process body change administer medication ( fluconazole atorvastatin ) . This study look lab result people take TAK-385 . The study enrol 40 patient . Participants assign one two treatment group : - TAK-385 40 mg fluconazole 400 mg Day 6 200 mg Days 7 14 - TAK-385 40 mg atorvastatin 80 mg Days 6-14 Participants fluconazole arm administer TAK-385 Days 1 10 fluconazole Days 6 14 . Participants atorvastatin arm administer TAK-385 Days 1 10 atorvastatin Days 6 14 . This single-center trial conduct United States . The overall time participate study 4 week . Participants make multiple visit clinic , include one 16-day period confinement clinic , final visit 7 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Inclusion Criteria Each subject must meet follow inclusion criterion enrol study : 1 . Age 18 55 year , inclusive , time consent . 2 . Healthy adult male female good health , determine physician evaluation 3 . Weight â‰¥ 45 kg body mass index ( BMI ) 18.0 30.0 kg/m2 , inclusive , screen . 4 . Nonsmoker use tobaccocontaining product ( include , limited , cigarette , pipe , cigar , chew tobacco , nicotine patch gum ) . Exclusion Criteria Subjects meeting follow exclusion criterion enrol study . 1 . The subject history drug abuse ( define illicit drug use ) within 1 year screen unwilling abstain drug throughout study . 2 . The subject unwilling agree abstain caffeine alcoholcontaining product 72 hour checkin ( Day 1 ) completion final assessment . 3 . The subject take prescription medicine herbal preparation ( eg , St John 's wort ) receive immunization within 30 day checkin ( Day 1 ) . 4 . The subject take counter ( OTC ) medication vitamin supplement within 14 day checkin ( Day 1 ) . The subject unwilling agree abstain consumption grapefruit grapefruitcontaining product 72 hour checkin ( Day 1 ) completion final assessment . 5 . The subject current recent ( within 6 month ) history gastrointestinal disease would expect influence absorption drug . 6 . The subject positive test result hepatitis B surface antigen , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibody antigen , serological reaction syphilis screen . 7 . The subject clinically significant ECG abnormality screen checkin ( Day 1 ) QTc interval ( Fridericia 's correction ) 450 msec great , subject history cardiac disease . 8 . The subject abnormal laboratory value suggest clinically significant disease screen checkin ( Day 1 ) . 9 . Female subject lactate breastfeed pregnant first dose study drug . 10 . Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>